SEC Form 4 · accession 0001209191-17-021139
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Owen N. Witte
Director
Period of report
Mar 14, 2017
Accepted (ET)
Mar 16, 2017 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 14, 2017 | A | 4,690 | $0.00 | A | 86,340 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $83.89 | Mar 14, 2017 | A | 17,130 | A | — | Mar 14, 2027 | Common Stock | 17,130 | 17,130 | D |
Explanation of responses
- F1The stock option shall vest in 36 equal monthly installments on the last day of each month following the date of grant.